Inactive Instrument

Agile Therapeutics, Inc.

AGRX

US00847L3087

Biotechnology & Medical Research

Agile Therapeutics, Inc. announced that it has received $45 million in funding from Perceptive Advisors LLC

March 28, 2021

On March 1, 2021, the company amended the terms of the transaction. The company now raised $45 million in the transaction. The investor provided additional $10 million in its fourth tranche close.

Latest news about Agile Therapeutics, Inc.

Exeltis USA, Inc. completed the acquisition of Agile Therapeutics, Inc. from Beryl Capital Management LLC and others.	24-08-25	CI
Agile Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-12	CI
Exeltis USA, Inc. entered into a definitive merger agreement to acquire Agile Therapeutics, Inc. for $10.7 million.	24-06-25	CI
Agile Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-15	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q1 Revenue $5.7M	24-05-15	MT
Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024	24-03-28
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M	24-03-28	MT
Agile Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	24-03-28	CI
Agile Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	24-03-27	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index	24-03-27	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index	24-03-24	CI
North American Morning Briefing : Stocks Struggle After New Records	24-03-22	DJ
North American Morning Briefing : Stock Futures -2-	24-03-19	DJ
Maxim Downgrades Agile Therapeutics to Hold From Buy	24-03-18	MT
Agile Therapeutics Inc. Completes Pay-Off the Remainder of its Debt Facility	24-03-14	CI
Top Premarket Gainers	24-02-22	MT
Agile Therapeutics, Inc. Announces Senior Secured Term Loan Credit Facility of Up to $35.0 Million	24-02-15	CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023	24-02-15	CI
Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-11-09	CI
Agile Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	23-11-09
Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023	23-11-09	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q3 Revenue $6.7M, vs. Street Est of $6.35M	23-11-09	MT
North American Morning Briefing : Traders Await -2-	23-11-09	DJ
North American Morning Briefing : Stock Futures -2-	23-09-25	DJ
Maxim Upgrades Agile Therapeutics to Buy From Hold With $5 Price Target	23-09-22	MT

Chart Agile Therapeutics, Inc.

Duration

Period

AGRX: Dynamic Chart

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.

Employees

Sector

Biotechnology & Medical Research

More about the company